• Late-Breaking Clinical Science Rules and Guidelines:

    1. Investigators may only submit unique unpublished research and warrant that the work is non-infringing upon any third party’s rights; data presented, accepted for presentation or publication at a U.S. or international meeting held before the SCAI Annual Scientific Sessions are not eligible for submission.
    2. Follow all instructions for completing the submission. Structure the LBCS abstract into Background, Methods, Results, and Conclusion sections.
    3. All authors are responsible for the contents and must have read and approved the manuscript, and conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals published in the Annals of Internal Medicine 1997; 126:36-47.
    4. Studies involving experimental animals and humans must conform to the guiding principles of the Declaration of Helsinki, and human subjects must have given informed consent of a study that has been approved by the Institutional Committee on Human Research at the author’s institution.
    5. Each presenting author must comply with the SCAI Disclosure Policy. Disclosure of relevant relationships with commercial entities is required for each presenting author. All speakers at SCAI’s Annual Scientific Sessions must display a slide at the beginning of their presentation indicating this disclosure information or nothing to disclose.
    6. The submitter (communicating author) acts on behalf of all co-authors and transfers to SCAI the copyright and all other rights in the material comprising the abstract if it is accepted. Co-authors reserve the following: a) all proprietary rights other than copyright, such as patent rights; and b) the right to use all or part of the application in future works of their own. SCAI reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats.
    7. SCAI requires all authors to read and comply with the SCAI embargo policy. Anyone determined to have violated the embargo policies may be withdrawn from the program or sanctioned as deemed necessary.

    • All LBCS abstracts are disclosed to the SCAI Program Committee, staff and contractors as necessary in connection with the annual meeting. Accepted LBCS abstracts are summarized for publication after the Annual Scientific Sessions and are not publicly available in advance of the meeting. Compliance with any disclosure or nondisclosure requirements that apply to researchers or research sponsors (whether under federal securities laws, contract agreement, or otherwise) is the sole responsibility of the researcher and/or sponsor, and not SCAI.
    • All authors, presenters, company sponsors, attendees, journalists and/or anyone with knowledge of embargoed content must comply with SCAI embargo policies, which state that scientific study results presented during the Annual Scientific Sessions must not be released prior to the time of presentation at the meeting or a SCAI-sponsored press conference, whichever comes first. Abstracts not selected for a press conference remain under embargo until the time of the presentation.
    • Presentation or discussion of scientific research at satellite meetings or non-SCAI press conferences prior to the scheduled Annual Scientific Sessions scientific presentation is strictly forbidden.
    • Investigator meetings: The only exceptions to the above-mentioned embargo rules are closed investigator meetings for participants in the trial. The SCAI Program Committee may ask you to supply investigator meeting date/time/location information if your LBCS abstract is accepted.
    • If media representatives contact authors, presenters and/or company sponsors, any information must be given with the understanding that scientific research results are to remain under embargo until the time of presentation or SCAI-sponsored press conference. Responsibility for information shared in this manner rests solely with the disclosing authors, presenters and/or company sponsors.
    • Authors, presenters, company sponsors, attendees, journalists, public relations firms, and/or anyone with knowledge of embargoed content must seek prior SCAI approval before publicly revealing any embargoed content for any reason. The SCAI leadership, press staff and meeting co-chairs will be available to work with the disclosing party to develop an acceptable release of the required information if specific disclosures (e.g., SEC requirements) must be met or in the case of public health concerns.


    Please contact SCAI Senior Meetings Manager Rachel Pham at rpham@scai.org or 202.741.9960.